We are live on ! Find out more
IMGN

Immunogen Inc

Delisted

IMGN was delisted on the 9th of February, 2024.

200 hedge funds and large institutions have $589M invested in Immunogen Inc in 2018 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 65 increasing their positions, 56 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

434% more call options, than puts

Call options by funds: $18.7M | Put options by funds: $3.49M

16% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 56

4% less funds holding

Funds holding: 208200 (-8)

16% less first-time investments, than exits

New positions opened: 38 | Existing positions closed: 45

50% less capital invested

Capital invested by funds: $1.18B → $589M (-$592M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
200
Holders Change
-8
Holders Change %
-3.85%
% of All Funds
4.46%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
38
Increased
65
Reduced
56
Closed
45
Calls
$18.7M
Puts
$3.49M
Net Calls
+$15.2M
Net Calls Change
+$529K
Name Holding Trade Value Shares
Change
Change in
Stake
S
176
SignatureFD
Georgia
$2K +$1.14K +187 +98%
HNB
177
Huntington National Bank
Ohio
$2K +$1.73K +285 +138%
CFGS
178
Concourse Financial Group Securities
Alabama
$2K +$3.49K +575 New
AssetMark Inc
179
AssetMark Inc
California
$1K
FHA
180
Flagship Harbor Advisors
Massachusetts
$1K
PNC Financial Services Group
181
PNC Financial Services Group
Pennsylvania
$1K +$218 +36 +16%
GRP
182
Global Retirement Partners
California
$1K +$297 +49 +21%
CA
183
Claro Advisors
Massachusetts
$1K +$710 +117 New
AC
184
Avestar Capital
New York
$1K +$1.19K +196 +15%
APA
185
American Portfolios Advisors
New York
$240
RCAG
186
Rehmann Capital Advisory Group
Michigan
$230
BNP Paribas Financial Markets
187
BNP Paribas Financial Markets
France
$182 -$25.4K -4,185 -99%
Capital Research Global Investors
188
Capital Research Global Investors
California
-$67.2M -7,095,570 Closed
O
189
OrbiMed
New York
-$13.9M -1,469,189 Closed
Allianz Asset Management
190
Allianz Asset Management
Germany
-$4.49M -473,846 Closed
MWNA
191
Marshall Wace North America
New York
-$4.04M -427,000 Closed
First Trust Advisors
192
First Trust Advisors
Illinois
-$2.7M -285,406 Closed
GC
193
Guggenheim Capital
Illinois
-$2.32M -244,847 Closed
Capital Fund Management (CFM)
194
Capital Fund Management (CFM)
France
-$954K -100,704 Closed
Alyeska Investment Group
195
Alyeska Investment Group
Illinois
-$947K -100,000 Closed
NA
196
Navellier & Associates
Nevada
-$876K -92,538 Closed
MOACM
197
Mutual of America Capital Management
New York
-$748K -79,000 Closed
ECM
198
Endurant Capital Management
California
-$607K -64,065 Closed
EIM
199
Essex Investment Management
Massachusetts
-$584K -61,676 Closed
Assenagon Asset Management
200
Assenagon Asset Management
Luxembourg
-$579K -61,112 Closed

IMGN Hedge Fund Activity: Q4 2018 in Review

200 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q4 2018, worth a combined $589M — down 50% from $1.18B a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of IMGN and 38 opened new positions — a net loss of 7 holders — while 56 trimmed existing stakes and 65 added.

The largest buyer was Millennium Management, adding an estimated $21.6M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $67.2M sold.

  • 200 institutional investors held Immunogen Inc (IMGN) as of Q4 2018, down from 208 in Q3 2018.
  • Funds reported $589M of Immunogen Inc stock for Q4 2018, down 50% quarter-over-quarter.
  • 38 funds opened new Immunogen Inc positions in Q4 2018 and 45 closed out, a net change of -7 holders.
  • The largest Immunogen Inc buyer in Q4 2018 was Millennium Management, an estimated $21.6M added.
  • The largest Immunogen Inc seller in Q4 2018 was Capital Research Global Investors, an estimated $67.2M sold.

Based on aggregated 13F filings for Q4 2018.